OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

     OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire

BOTHELL, WA and VANCOUVER, March 28, 2013

BOTHELL, WA and VANCOUVER, March 28, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc.(NASDAQ: OGXI) announced today that Scott Cormack,
President and Chief Executive Officer, will provide a corporate presentation
at the Future Leaders in the Biotech Industry  Conference on Friday, April 5,
2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in New York City.

A live audio webcast can be accessed through the Investor Relations page of
the OncoGenex website atwww.oncogenex.com. The webcast replay will be
archived for 60 days.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com

.

SOURCE OncoGenex Pharmaceuticals, Inc.

Contact:

Media Contact:
Jaime Welch
jwelch@oncogenex.com
604-630-5403

Investor Relations Contact:
Susan Specht
sspecht@oncogenex.com
425-686-1535
 
Press spacebar to pause and continue. Press esc to stop.